Skip to search formSkip to main contentSkip to account menu

SU 11654

Known as: SU-11654, SU11654 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Spontaneous cancers are common in the pet dog population with estimated 60% of dogs that live to 10 years of age developing… 
2010
2010
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… 
Review
2010
Review
2010
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… 
Highly Cited
2009
Highly Cited
2009
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… 
2006
2006
OBJECTIVE To evaluate canine histiocytic sarcoma cell lines and tumor samples for dysregulation of the Kit/stem-cell factor (SCF… 
Highly Cited
2003
Highly Cited
2003
PURPOSE The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone… 
Highly Cited
2003
Highly Cited
2003
PURPOSE The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of… 
Highly Cited
2002
Highly Cited
2002
Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the negative regulatory…